

August 30, 2025

To, Listing/ Compliance Department **BSE LTD.** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

**SCRIP CODE: 543748** 

Dear Sir/Madam,

To, Listing/ Compliance Department National Stock Exchange of India Limited "Exchange Plaza", Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

**SYMBOL: AARTIPHARM** 

**Sub:** Newspaper Advertisements

**Ref:** Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements)

Regulations, 2015

We are enclosing herewith copies of the newspaper advertisements published in Financial Express (English) and Loksatta-Jansatta (Gujarati), regarding completion of electronic dispatch to the Shareholders of Annual Report for the Financial Year 2024-25 and Notice of the 6<sup>th</sup> Annual General Meeting of the Company which is scheduled to be held on **Monday, September 22, 2025 at 11:00 AM (IST)** through Video Conferencing (VC) / Other Audio Visual Means (OAVM).

A copy of the advertisement is also available on the website of the Company – www.aartipharmalabs.com.

Please take the same on your records.

Thanking you,

Yours faithfully,

For AARTI PHARMALABS LIMITED

Jeevan Mondkar

COMPANY SECRETARY AND LEGAL HEAD

ICSI M. NO. A22565

Encl: a/a



Aarti Pharmalabs Limited
CIN: L24100GJ2019PLC110964
Regd. Off.: Plot No. 22/C/1 & 22/C/2, 1st Phase, G.I.D.C. Vapi- 396195, Dist. Valsad, Gujarat Website: www.aartipharmalabs.com Email: investorrelations@aartipharmalabs.com Telephone: +91 260 2400467, +91 99099 94655
NOTICE OF 61h ANNUAL GENERAL MEETING,
E-VOTING INFORMATION

- Website: www.aartiphamslabs.com Email: investorelations@aartiphamslabs.com
  Teleptone: +1 280 360 48 49 380 38 4865

  NOTICE OF CONTROL INFORMATION

  NOTICEIS HEREBY GIVEN THAT:

  1. The 6" Annual General Meeting of the Members of Aarti Pharmalabs Limited ("the Company") will be held on Monday, September 22, 2025 at 11:00 a.m. (IST) through Video Conferencing ("CVC") Other Audio-Visual Means ("OA/M") to transact the business are allowed to the company of the Members of Aarti Pharmalabs Limited ("the Company") will be held on Monday, September 22, 2025 at 11:00 a.m. (IST) through Video Conferencing ("CVC") Other Audio-Visual Means ("OA/M") to transact the business are allowed to the Members of Company and the Circulars' ("MCA") and issued by Securitic and Exchange Board of India ("SEEI") (hereinafter collectively referred to as "the Circulars"), Companies are allowed to hold the AGM through VC, without the physical presence of members at a common venue. Hence the AGM of the Company is being held through VC/OAVM to transact the business as setforth in the notice of the AGM. Financial year 2024-25 has been sent to those members whose email ID is not registered with Company/ MUFG Intime India Limited ("TRA")Depository Participants ("DP").

  2. In compliance with the said circulars, Notice of the AGM along with the Annual Report for 2024-25, has been sent, through electronic mode to those Members, whose email available on the website of the Company at https://www.waaritphamalabs.com/annual-reports and websites of the Stock Exchanges i.e. BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") at twww.bseindia.com and www.nseindia.com respectively, and also on the website of National Securities Depository Limited ("NSE") at www.bseindia.com and www.nseindia.com respectively, and also on the website of National Securities Depository Limited ("NSE") at www.bseindia.com and www.nseindia.com respectively, and also on the website of National Securities Depository Limited ("NSE") at www.bseindia.com on www.nsei

- 8. Members shall be able to attend the AGM through VC/OAVM or view the live webcast of AGM provided by NSDL at <a href="www.evoting.nsdl.com">www.evoting.nsdl.com</a> by using their remote e-voting login credentials and selecting the EVEN(135781) for Company's AGM. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of ascertaining the quorum Section 103 of the Act.

  Process for registering E-mail addresses:

  9. Please provide DPID-CLID, name, dient master or copy of consolidated account statement, PAN(self-attested), AADHAR (self-attested) to investorrelations@aartipharmalabs.com.

  10. Alternatively members may send an email request to evoting@nsdl.co.in for obtaining User ID and password by providing the details mentioned in Point (9).

  11. In case of any assistance, members may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for shareholders available at the download section of NSDL at <a href="www.evoting.nsdl.com">www.evoting.nsdl.com</a> or call on toll free no.: 022 48867000 or senda request to Ms. Prajakta Pawle, Executive Manager-NSDL at email: <a href="www.evoting.nsdl.com">evoting@nsdl.co.in</a>. Saksham Niveshak <a href="wmmner-of-registering-KYC">Manner of-registering-KYC</a> including bank details for <a href="www.evoting.nsdl.com">receiving dividend</a>:

  Pursuant to the MCA circular dated July 16, 2025, Company has initiated a 100 days campaign for updation of KYC and other related details of members including bank details to prevent transfer of unpaid / unclaimed dividends to IEPF. Details of unpaid / unclaimed dividends lying with the Company are available on <a href="https://www.aartipharmalabs.com/undaimed-dividends">https://www.aartipharmalabs.com/undaimed-dividends</a>.

- - com/undaimed-dividends.

    For claiming the unpaid / unclaimed dividends, the members are requested to update their KYC for shares held in dematerialized form with the Depository Participant (DP) where the demat account is maintained as per the process advised by DP.

    Upon updation of KYC & bank details members are requested to intimate the same to the RTA so that the unpaid/unclaimed dividend can be credited to their bank account.

By order of the Board of Directors For Aarti Pharmalabs Limited Sd/-JEEVAN MONDKAR COMPANY SECRETARY AND LEGAL HEAD ICSI M. NO. A22565

Mumbai / August 29, 2025



અારલી કામહિલ્ય લિગ્રેક CN: L241006J2019PLC110964 નોંધણી થચેલ ઓફ્સિઃ પ્લોટ નંબર 22/C/1 એને 22/C/2, પહેલાં તબક્કો, G.I.D.C. વાપી- ૩૯૬૧૯૫, જિ. વલસાડ, ગુજરાત વેબસાઇટ: www.aartipharmalabs.com ઇમેઇલઃ investorrelations@aartipharmalabs.com ટેલિફોન: +91 260 2400467, +91 99099 94655

## છટ્ટી વાર્ષિક સામાન્ય સભાની સૂચના, ઈ-વોટિંગ માહિતી

આરતી ફાર્માલેબ્સ લિમિટેડ માટે Sd/-જીવન મોંડકર કંપની સચિવ અને કાનૂની વડા

ICSI M. oi. A22565

મુંબઈ / રહ ઓગસ્ટ, ૨૦૨૫